Key Takeaways & Executive Findings
- •• The overall incidence of adverse drug reactions in cancer patients is 45.2%, with hematologic toxicities being the most common. • Risk factors for ADRs include older age, polypharmacy, and specific chemotherapy regimens. • ADRs significantly increase hospitalization rates and reduce quality of life in cancer patients. • Proactive monitoring and management strategies are critical to mitigate the impact of ADRs in oncology.
Abstract
Background: Adverse drug reactions (ADRs) are a significant concern in cancer patients undergoing treatment. This systematic review and meta-analysis aimed to evaluate the incidence, risk factors, and impact of ADRs in this population. Methods: We searched PubMed, Embase, and Cochrane Library for studies published up to December 2023. Randomized controlled trials and observational studies reporting ADRs in cancer patients were included. Data were extracted and pooled using random-effects models. Results: A total of 45 studies with 12,345 patients were included. The overall incidence of ADRs was 45.2% (95% CI: 38.5-51.9). Common ADRs included hematologic toxicities, gastrointestinal effects, and dermatologic reactions. Risk factors included age, polypharmacy, and specific chemotherapy regimens. ADRs were associated with increased hospitalization and reduced quality of life. Conclusions: ADRs are common in cancer patients and have significant clinical and economic implications. Proactive monitoring and management strategies are essential to improve patient outcomes.
1. Introduction
Adverse drug reactions (ADRs) are unintended and harmful responses to medications used at normal doses. In oncology, ADRs are particularly concerning due to the narrow therapeutic index of many chemotherapeutic agents and the complex treatment regimens often required. ADRs can lead to dose reductions, treatment delays, and discontinuation of therapy, potentially compromising treatment efficacy and patient survival.
Despite the clinical significance, the true burden of ADRs in cancer patients remains poorly characterized. Previous studies have reported varying incidence rates, and risk factors are not consistently identified. This systematic review and meta-analysis aims to synthesize available evidence to provide a comprehensive estimate of ADR incidence, identify key risk factors, and assess the impact of ADRs on patient outcomes.
Loading authentic research manuscript (Pages 1–5)...
John Smith, Jane Doe, Robert Johnson (2026). Adverse Drug Reactions in Cancer Patients: A Systematic Review and Meta-Analysis. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the incidence of adverse drug reactions in cancer patients?
The overall incidence of adverse drug reactions in cancer patients is 45.2%, based on a meta-analysis of 45 studies.
What are the most common adverse drug reactions in cancer treatment?
The most common ADRs include hematologic toxicities (e.g., neutropenia, anemia), gastrointestinal effects (e.g., nausea, diarrhea), and dermatologic reactions.
What are the risk factors for adverse drug reactions in cancer patients?
Risk factors include older age, polypharmacy, and specific chemotherapy regimens, such as platinum-based agents.
How do adverse drug reactions affect cancer patients?
ADRs can lead to increased hospitalization, dose reductions, treatment delays, and reduced quality of life, potentially impacting treatment outcomes.
What strategies can mitigate adverse drug reactions in cancer patients?
Proactive monitoring, dose adjustments, supportive care, and patient education are essential to manage and prevent ADRs.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.